Blood
Articles in this Issue
Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study
Abstract Background: Multiple myeloma (MM) is still an incurable neoplasm, and treatment options for heavily pretreated relapsed and refract...
Efficacy and safety of loncastuximab tesirine and rituximab (Lonca-R) followed by dose-adjusted rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine and prednisone (DA-R-EPOCH) in previously untreated high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary results from a University of California Malignancy Consortium (UCHMC) Phase II trial, UCDCC#303.
Abstract Background: Newly diagnosed DLBCL is a potentially curable malignancy. However, there are high-risk subsets that respond poorly to...
Evaluating the efficacy and safety of gene therapy in transfusion-dependent β-thalassemia: A focus on hemolysis improvement and clonal hematopoiesis monitoring
Abstract Background. Gene therapy (GT) has emerged as a transformative treatment for transfusion-dependent β-thalassemia (TDT) and sickle ce...
Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1
Abstract Background: Despite significant advances, multiple myeloma (MM) remains incurable and new therapies are needed to improve outcomes....
Sensitive detection of novel structural variants and 3D chromosome conformation reveals likely novel drivers including enhancer hijacking in AML
Abstract Introduction: Extensive characterization of the genetic landscape in AML has revealed a set of driver mutations sufficient to initi...
VTE outcomes in hemoglobinopathy patients: A propensity-matched analysis. insights from the riete registry.
Abstract Introduction: Patients with hemoglobinopathies, such as sickle-cell disease and thalassemia, are associated with higher rates of ve...
AI-based characterization of terminal erythroid differentiation as a prognostic biomarker in myelodysplastic syndromes
Abstract Flow cytometry has demonstrated significant alterations in terminal erythroid differentiation (TED) in patients with myelodysplasti...
Personalized prognostic model for multiple myeloma patients using continuous variables
Abstract Introduction. Multiple Myeloma (MM) represents a malignant hematological disease characterized by significant inter-patient and int...
Vitamin d deficiency as a predictive and prognostic tool in aggressive lymphomas in Peru: A multicenter cohort study
Abstract Introduction. Vitamin D deficiency has been linked to reduced survival in cancer patients, though evidence is still inconclusive. I...
Number needed to treat to avoid progression or death: Zanubrutinib vs other COVALENT bruton tyrosine kinase inhibitors in Relapsed/Refractory chronic lymphocytic leukemia
Abstract Introduction Bruton tyrosine kinase inhibitors (BTKis) have changed the treatment algorithm for patients with high-risk relapsed/re...
High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients
Abstract BACKGROUND Our group (Gazeau et al., TCT 2023) and others showed the safety and potential efficacy of treatment with the recombinan...
Single-cell analysis identifies a KLF5–Neutrophil–Plasma cell axis driving immune suppression in POEMS syndrome
Abstract Introduction: POEMS syndrome is a rare clonal plasma cell disorder characterized by complex manifestations, marked heterogeneity, a...
Evaluation of large language models in lymphoma clinical scenarios: A comparative analysis
Abstract Backgrounds: The growing accessibility of general-purpose large language models (LLMs) has prompted increased u...
Immune and DNA-damage responses in the intestinal stroma of patients presenting with lower gastro-intestinal symptoms after allogeneic stem cell transplantation
Abstract Introduction Infection and immune-driven inflammation of the gut often result in severe intestinal dysfunction or even end-organ di...
Multiple medication use is associated with increased lymphoma risk in autoimmune diseases: Analysis from the life study
Abstract Autoimmune diseases (AIDs) are associated with an increased risk of lymphoma. The risk is influenced not only by the nature and sev...
Characterization of bone marrow B-cells in patients with warm autoimmune hemolytic anemia by single-cell analysis
Abstract Warm autoimmune hemolytic anemia (wAIHA) is a rare disorder caused by IgG autoantibodies targeting autologous erythrocytes. These a...
Cytogenetic and molecular risk predict survival in AML independent of age and treatment intensity
Abstract Background: Cytogenetic and molecular features are critical to prognostication and treatment planning in acute myeloid leukemia (AM...
Efficacy and safety of long-term odronextamab treatment in patients with relapsed/refractory follicular lymphoma: 3-year follow-up from the Phase 2 ELM-2 study
Abstract Introduction Odronextamab, a CD20×CD3 bispecific antibody, demonstrated compelling efficacy with a generally manageable safety profi...
Targeting the CD38-NAD⁺ axis alleviates antibody-driven cytopenia in autoimmune disorders without inducing broad immunosuppression
Abstract Autoimmune diseases, including immune thrombocytopenia (ITP), are typically managed through long-term non-specific immunosuppressio...
A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL)
Abstract Background: The receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a transmembrane protein that is overexpressed in multiple...
Exercise capacity and oxygen saturation on six-minute walk testing relate to markers of organ dysfunction in adults with sickle cell disease
Abstract Introduction: Dyspnea and reduced exercise capacity are common in adults with sickle cell disease (SCD); the etiology is often mult...
Comparative efficacy of novel therapies for sickle cell disease: A network meta-analysis of hydroxyurea, voxelotor, crizanlizumab, and l-glutamine
Abstract Background: Multiple pharmacologic agents are now approved for the management of sickle cell disease (SCD), inc...
Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database
Abstract Introduction: HMA monotherapy (HMAm) continues to be the standard of care for HR-MDS. While the addition of VEN to azacitidine (AZA...
Pre-transplant minimal residual disease (MRD) negativity predicts superior GVHD-free/relapse-free survival after allogeneic HCT in pediatric acute lymphoblastic leukemia
Abstract Introduction: Allogeneic HCT is the only curative option for children with high-risk, relapsed, or refractory acute lymphoblastic l...
The psychometric properties of the stoplight pain scale in children with sickle cell disease
Abstract Background: Effective pain management begins with accurate pain assessment for children with sickle cell disease (SCD) experiencing...